Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the transaction, the executive vice president now directly owns 26,512 shares in the company, valued at approximately $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Vertex Pharmaceuticals Stock Performance
Shares of VRTX opened at $495.42 on Thursday. The firm has a market capitalization of $127.22 billion, a P/E ratio of -225.19, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The stock has a 50 day moving average price of $453.85 and a two-hundred day moving average price of $461.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on VRTX shares. Cantor Fitzgerald reissued an "overweight" rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Bank of America lowered their price objective on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a "buy" rating for the company in a research report on Thursday, December 19th. Truist Financial raised their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Oppenheimer cut Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Thursday, December 19th. Finally, Barclays boosted their target price on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 11th. Ten equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $506.70.
Read Our Latest Research Report on Vertex Pharmaceuticals
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in VRTX. Dunhill Financial LLC increased its stake in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 24 shares during the last quarter. Brown Lisle Cummings Inc. bought a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Legacy Investment Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $33,000. Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals during the third quarter worth $35,000. Finally, Sugar Maple Asset Management LLC purchased a new position in Vertex Pharmaceuticals in the fourth quarter worth $35,000. 90.96% of the stock is owned by institutional investors.
About Vertex Pharmaceuticals
(
Get Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
